Control Bionics Ltd.

Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. It operates through the following segments: Australia, US, International, R&D, and Corporate. The Australia segment is involved with the sales of Trilogy units and components in Australia. The US segment refers to Manufacture and sales of Trilogy units and components in North America. The International segment deals with the activities undertaken to establish viable and additional operating segments. The R&D segment pertains to the Research activities undertaken regarding the Group's products. The Corporate segment offers support, regulatory and infrastructure activities, and elimination entries above the EBITDA line. The company was founded by Peter Shann Ford in 2005 and is headquartered in Sydney, Australia.